vs

Side-by-side financial comparison of Kymera Therapeutics, Inc. (KYMR) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

Kymera Therapeutics, Inc. is the larger business by last-quarter revenue ($11.5M vs $9.6M, roughly 1.2× Red Cat Holdings, Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -667.6%, a 501.6% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs -55.3%). Red Cat Holdings, Inc. produced more free cash flow last quarter ($-24.5M vs $-60.6M).

Kymera Therapeutics is a clinical-stage biopharmaceutical company specialized in developing innovative targeted protein degradation therapies. It advances a diversified pipeline of drug candidates targeting previously undruggable proteins to address unmet medical needs in oncology, autoimmune and inflammatory diseases worldwide.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

KYMR vs RCAT — Head-to-Head

Bigger by revenue
KYMR
KYMR
1.2× larger
KYMR
$11.5M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+1043.5% gap
RCAT
988.2%
-55.3%
KYMR
Higher net margin
RCAT
RCAT
501.6% more per $
RCAT
-166.0%
-667.6%
KYMR
More free cash flow
RCAT
RCAT
$36.1M more FCF
RCAT
$-24.5M
$-60.6M
KYMR

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
KYMR
KYMR
RCAT
RCAT
Revenue
$11.5M
$9.6M
Net Profit
$-76.6M
$-16.0M
Gross Margin
6.6%
Operating Margin
-736.8%
-181.7%
Net Margin
-667.6%
-166.0%
Revenue YoY
-55.3%
988.2%
Net Profit YoY
-82.1%
-29.0%
EPS (diluted)
$-0.95
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KYMR
KYMR
RCAT
RCAT
Q3 25
$9.6M
Q2 25
$11.5M
Q1 25
$22.1M
$1.6M
Q4 24
$7.4M
$0
Q2 24
$25.6M
Q1 24
$10.3M
$5.8M
Q4 23
$47.9M
Q2 23
$16.5M
Net Profit
KYMR
KYMR
RCAT
RCAT
Q3 25
$-16.0M
Q2 25
$-76.6M
Q1 25
$-65.6M
$-23.1M
Q4 24
$-70.8M
$-13.3M
Q2 24
$-42.1M
Q1 24
$-48.6M
$-5.5M
Q4 23
$-14.4M
Q2 23
$-38.8M
Gross Margin
KYMR
KYMR
RCAT
RCAT
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
Q2 24
Q1 24
18.8%
Q4 23
Q2 23
Operating Margin
KYMR
KYMR
RCAT
RCAT
Q3 25
-181.7%
Q2 25
-736.8%
Q1 25
-336.8%
-765.7%
Q4 24
-1092.2%
Q2 24
-198.5%
Q1 24
-562.2%
-76.0%
Q4 23
-40.3%
Q2 23
-262.7%
Net Margin
KYMR
KYMR
RCAT
RCAT
Q3 25
-166.0%
Q2 25
-667.6%
Q1 25
-296.7%
-1418.9%
Q4 24
-956.9%
Q2 24
-164.0%
Q1 24
-472.0%
-93.9%
Q4 23
-30.0%
Q2 23
-235.0%
EPS (diluted)
KYMR
KYMR
RCAT
RCAT
Q3 25
$-0.16
Q2 25
$-0.95
Q1 25
$-0.82
$-0.27
Q4 24
$-0.89
Q2 24
$-0.58
Q1 24
$-0.69
Q4 23
$-0.25
Q2 23
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KYMR
KYMR
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$335.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$971.5M
$253.3M
Total Assets
$1.1B
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KYMR
KYMR
RCAT
RCAT
Q3 25
Q2 25
$335.8M
Q1 25
$90.0M
Q4 24
$120.3M
Q2 24
$67.6M
Q1 24
$93.5M
Q4 23
$110.0M
Q2 23
$52.4M
Stockholders' Equity
KYMR
KYMR
RCAT
RCAT
Q3 25
$253.3M
Q2 25
$971.5M
Q1 25
$786.2M
$28.9M
Q4 24
$835.6M
$27.0M
Q2 24
$684.9M
Q1 24
$711.2M
$49.6M
Q4 23
$395.0M
Q2 23
$435.4M
Total Assets
KYMR
KYMR
RCAT
RCAT
Q3 25
$286.0M
Q2 25
$1.1B
Q1 25
$918.3M
$59.7M
Q4 24
$978.0M
$51.1M
Q2 24
$826.0M
Q1 24
$868.3M
$55.3M
Q4 23
$575.8M
Q2 23
$581.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KYMR
KYMR
RCAT
RCAT
Operating Cash FlowLast quarter
$-59.9M
$-23.9M
Free Cash FlowOCF − Capex
$-60.6M
$-24.5M
FCF MarginFCF / Revenue
-527.9%
-254.2%
Capex IntensityCapex / Revenue
6.1%
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-250.5M
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KYMR
KYMR
RCAT
RCAT
Q3 25
$-23.9M
Q2 25
$-59.9M
Q1 25
$-79.2M
$-15.9M
Q4 24
$-61.8M
$-10.1M
Q2 24
$-42.9M
Q1 24
$-39.6M
$-4.1M
Q4 23
$8.0M
Q2 23
$-35.3M
Free Cash Flow
KYMR
KYMR
RCAT
RCAT
Q3 25
$-24.5M
Q2 25
$-60.6M
Q1 25
$-79.6M
$-16.2M
Q4 24
$-62.7M
$-10.2M
Q2 24
$-47.6M
Q1 24
$-47.0M
$-4.2M
Q4 23
$-3.6M
Q2 23
$-46.0M
FCF Margin
KYMR
KYMR
RCAT
RCAT
Q3 25
-254.2%
Q2 25
-527.9%
Q1 25
-360.3%
-992.9%
Q4 24
-848.3%
Q2 24
-185.7%
Q1 24
-456.8%
-71.1%
Q4 23
-7.5%
Q2 23
-278.7%
Capex Intensity
KYMR
KYMR
RCAT
RCAT
Q3 25
6.9%
Q2 25
6.1%
Q1 25
2.1%
16.8%
Q4 24
12.7%
Q2 24
18.3%
Q1 24
72.0%
0.8%
Q4 23
24.3%
Q2 23
65.2%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KYMR
KYMR

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons